Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04699903 Completed - SARS-Cov-2, Covid19 Clinical Trials

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

Start date: January 5, 2021
Phase:
Study type: Observational

Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.

NCT ID: NCT04699227 Completed - Covid19 Clinical Trials

Can RIC Prevent Deterioration to Critical Care in Covid19

Start date: January 15, 2021
Phase: N/A
Study type: Interventional

The coronavirus disease (COVID-19) emerged in late 2019 and has since been diagnosed in over a million persons worldwide. As this virus progresses, it causes an extreme and uncontrolled response from the patient's immune system accompanied by reduced oxygen flow to major organs, and subsequent ischaemic injury. The current treatment of COVID-19 is largely supportive without any cure or vaccine available at this time. Developing new methods to reduce this heightened inflammatory response is essential to halting progression of COVID-19 in patients and reducing the severity of damage. The cellular mechanisms seen in COVID-19 are similar to those seen in patients with sepsis. A process known as Remote Ischemic Conditioning (RIC) is an intervention which has been shown to prevent cellular injury including those associated with sepsis. Based on the evidence from studies looking at sepsis, it is anticipated the same benefit would be seen in patients diagnosed with COVID-19. RIC is a simple, non-invasive procedure where a blood pressure cuff is applied to the arm for repeated cycles of inflating and deflating (typically 3-5 cycles of 5 minutes each). This process activates pro-survival mechanisms in the body to protect vital organs and improve the immune system. Therefore, we believe it represents an exciting strategy to protect organs against reduced blood flow and extreme immune response, as seen in COVID-19 infections. This study has already been fully approved

NCT ID: NCT04699097 Completed - Covid19 Clinical Trials

The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children

Start date: July 1, 2020
Phase:
Study type: Observational

Azithromycin (AZ) is used in the pediatric group in COVID-19 diseas. It has been reported to cause prolongation in the QT interval in adult age group. The aim of this study is to evaluate the effect of AZ on ventricular repolarization in COVID-19 positive pediatric patients. METHOD The study was conducted prospectively in July-August 2020. COVID-19 pediatric patients who received AZ treatment were included in the study. ECG was obtained before treatment and on the 1st, 3rd and 5th days after the treatment. Measurements were made with Image J program®. QTmax, QTmin, Tp-emax, Tp-emin intervals were measured. QTcmax, QTcmin, Tp-ecmax, Tp-ecmin, QTcd, Tp-ecd, and QTc / Tp-ec ratios were calculated with Bazett formula.

NCT ID: NCT04698837 Completed - SARS-CoV-2 Clinical Trials

Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2

aeroCOVID1
Start date: February 2, 2021
Phase:
Study type: Observational

Modes of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and specifically the proportion of airborne transmission in this infection is unknown. In the aeroCOVID study, a highly efficient bioaerosol and droplet sampling dummy is used to emulate a susceptible healthcare worker (HCW) and to perform patient proximity sampling. The dummy will measure the dummy-inhaled dose of SARS-CoV-2 in two particle size fractions in a standardized interaction with hospitalized coronavirus disease 2019 (COVID-19) patients. All measurements are performed in a masked and unmasked dummy setup in parallel, in order to gain further information on the protection of type II masks against the respective particle size exposure.

NCT ID: NCT04698083 Completed - Covid19 Clinical Trials

Electrocardiographic QRS Axis Shift ,Rotation and COVİD-19

Start date: July 22, 2020
Phase:
Study type: Observational

In patients with coronavirus disease (COVID-19), severe dyspnea is the most dramatic complication.Severe respiratory difficulties may include electrocardiographic frontal QRS axis rightward shift (Rws) and clockwise rotation (Cwr). This study investigated the predictability of advanced lung tomography findings with QRS axis shift and rotation. This was a retrospective analysis of 160 patients.The patients were divided into two groups: normal oxygen saturation(SpO2) (NS; n = 80) and low SpO2(LS;n = 80).They were then divided into NS Rws (n = 37), NS leftward shift (Lws; n = 43), LS Rws (n = 40), and LS Lws (n = 40) according to electrocardiographic follow-up findings. These groups were compared in terms of electrocardiographic rotation (Cwr, counterclockwise rotation, or normal transition), tomographic stage (CO-RADS5(advanced)/CO-RADS1-4), electrocardiographic intervals, and laboratory findings

NCT ID: NCT04698044 Completed - Depression Clinical Trials

Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period

Start date: May 8, 2020
Phase:
Study type: Observational

The COVID-19 pandemic has negatively affected individuals not only physiologically but also psychologically. The aim of this study is to examine the anxiety and depression status of cancer patients, individuals with non-cancer chronic diseases and healthy individuals with an online screening questionnaire during the COVID-19 pandemic period.

NCT ID: NCT04697654 Completed - COVID-19 Clinical Trials

The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers

Start date: October 8, 2020
Phase: Phase 1
Study type: Interventional

Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability, and PK of single ascending doses of inhaled TLC19 in healthy volunteer subjects.

NCT ID: NCT04697030 Completed - Covid-19 Pandemic Clinical Trials

Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan

Start date: September 15, 2020
Phase:
Study type: Observational

The lethal severe acute respiratory syndrome coronavirus 2 (SARS-COV2) which caused the COVID-19 pandemic starting at the end of 2019 has affected the lives of children and adolescents globally. world adopted the lockdown to prevent spread of the infection and protect the population. lockdown suspended out of home activities of almost everyone, along with health benefits, yielding some side effects as well including burnout. The burnout includes physical and emotional burnout, physical burnout refers to the lack of interest in any physical activity to the point of a rebel and the emotional burnout of teenagers refers to a syndrome including features such as behavior changes, thinking change, feeling change, health change leading to stress and other pathological disturbances. Together the external and internal factors lead to overall personality destruction. It was an observational study with a sample size of 443 participants.

NCT ID: NCT04696562 Completed - COVID-19 Clinical Trials

The Effect of Deep Breathing Exercise on Dyspnea, Anxiety and Quality of Life in Patients Treated for COVID-19

Start date: January 11, 2021
Phase: N/A
Study type: Interventional

The world is facing an extremely important global epidemic. Coronavirus disease 2019 (COVID-19) epidemic, which first appeared in Wuhan, China in late 2019 and rapidly affected all countries of the world, was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020. Coronavirus disease 2019 affects both the upper (i.e. sinuses, nose and throat) and lower (i.e. trachea and lungs) airways, causes respiratory tract diseases ranging from asymptomatic or cold to more severe lung diseases (Acute Respiratory Distress Syndrome-ARDS). COVID-19 has many symptoms (i.e. fever, loss of appetite). In cases where the disease has a more severe course, in addition to the symptoms mentioned above, complications such as a severe pneumonia, acute respiratory distress syndrome (ARDS) kidney failure and fatal heart damage may develop. Dyspnea is one of the most prominent symptoms for COVID-19. Since COVID-19 affects the respiratory system, pulmonary rehabilitation has an important place in the treatment of patients. Dyspnea is one of the most prominent symptoms for COVID-19. Our clinical observations are of the opinion that dyspnea is observed even in patients with mild COVID-19 pneumonia. Applying deep breathing exercise with triflo in COVID-19 patients, can contribute to relieving dyspnea, reducing / eliminating anxiety, and increasing quality of life. In the light of this information, the aim of this study is to determine the effect of deep breathing exercise with triflo on dyspnea, anxiety and quality of life in patients with dyspnea who are hospitalized for COVID-19. Research Hypotheses H1: Patients with COVID-19 pneumonia who undergo deep breathing exercise with triflo will have a lower dyspnea level than the patient group in which this exercise is not applied. H2: Patients with COVID-19 pneumonia who underwent deep breathing exercise with triflo will have a lower anxiety level than the patient group in whom this exercise was not applied. H3: Patients with COVID-19 pneumonia who underwent deep breathing exercise with triflo will have a higher quality of life than the patient group in whom this exercise was not applied.

NCT ID: NCT04695678 Completed - COVID-19 Clinical Trials

Epidemiological Multicohort Study of Latent COVID-19 Infections

Start date: July 1, 2020
Phase:
Study type: Observational

Cross-sectional study to detect latent COVID-19 infections in residents and staff of old people's and nursing homes in the city of Solingen with a prospective follow-up of 6 months in a subgroup.